Meso Numismatics Changes Name to Regenerative Medical Technology Group and Ticker Symbol to RMTG
Regenerative Medical Technology Group Inc. (formerly Meso Numismatics, Inc.) has announced a significant corporate rebranding, changing its name and stock symbol to RMTG. This change, effective October 21, 2024, marks the company's complete transition from numismatics to biotechnology and regenerative medicine.
CEO David Christensen expressed excitement about this milestone, emphasizing the company's belief in regenerative medicine as the future of health healing. The company plans to leverage the latest knowledge, inclusive technology, and hands-on training through its International Society for Stem Cell Applications (ISSCA).
The global Regenerative Medicine Market, valued at approximately $35 billion in 2022, is projected to grow to over $190 billion by 2032. RMTG aims to position itself in this rapidly expanding field by developing advanced therapies for tissue and organ repair, regeneration, and revitalization.
Regenerative Medical Technology Group Inc. (precedentemente nota come Meso Numismatics, Inc.) ha annunciato un'importante riorganizzazione aziendale, cambiando il suo nome e simbolo azionario in RMTG. Questa modifica, effettiva dal 21 ottobre 2024, segna la completa transizione dell'azienda dalla numismatica alla biotecnologia e medicina rigenerativa.
Il CEO David Christensen ha espresso entusiasmo per questo traguardo, sottolineando la convinzione dell'azienda che la medicina rigenerativa rappresenti il futuro della guarigione della salute. L'azienda prevede di sfruttare le ultime conoscenze, tecnologie inclusive e formazione pratica attraverso la sua International Society for Stem Cell Applications (ISSCA).
Il mercato globale della medicina rigenerativa, valutato a circa 35 miliardi di dollari nel 2022, è previsto crescere oltre i 190 miliardi di dollari entro il 2032. RMTG punta a posizionarsi in questo settore in rapida espansione sviluppando terapie avanzate per la riparazione, rigenerazione e rivitalizzazione dei tessuti e degli organi.
Regenerative Medical Technology Group Inc. (anteriormente conocido como Meso Numismatics, Inc.) ha anunciado una importante rebranding corporativo, cambiando su nombre y símbolo de acciones a RMTG. Este cambio, que será efectivo a partir del 21 de octubre de 2024, marca la completa transición de la empresa de la numismática a la biotecnología y medicina regenerativa.
El CEO David Christensen expresó su entusiasmo por este hito, enfatizando la creencia de la empresa en la medicina regenerativa como el futuro de la sanación de la salud. La empresa planea aprovechar los últimos conocimientos, tecnología inclusiva y formación práctica a través de su International Society for Stem Cell Applications (ISSCA).
El mercado global de Medicina Regenerativa, valorado en aproximadamente 35 mil millones de dólares en 2022, se proyecta que crecerá a más de 190 mil millones de dólares para 2032. RMTG aspira a posicionarse en este campo de rápido crecimiento desarrollando terapias avanzadas para la reparación, regeneración y revitalización de tejidos y órganos.
재생 의료 기술 그룹 주식회사 (이전 이름: 메소 누미스매틱스 주식회사)는 중요한 기업 리브랜딩을 발표하며 이름과 주식 기호를 RMTG로 변경했습니다. 이 변화는 2024년 10월 21일부터 시행되며, 회사의 금속 화폐 수집에서 생명공학 및 재생 의학으로의 완전한 전환을 의미합니다.
CEO 데이비드 크리스텐슨은 이 이정표에 대한 기대감을 표명하며, 재생 의학이 건강 치유의 미래라는 회사의 신념을 강조했습니다. 회사는 국제 줄기세포 응용 사회 (ISSCA)를 통해 최신 지식, 포괄적인 기술, 실습 교육을 활용할 계획입니다.
전 세계 재생 의학 시장은 2022년 약 350억 달러로 평가되며, 2032년까지 1,900억 달러 이상 성장할 것으로 예상됩니다. RMTG는 조직 및 장기의 수리, 재생 및 회복을 위한 첨단 치료법을 개발함으로써 이 빠르게 성장하는 분야에 자리 잡을 계획입니다.
Regenerative Medical Technology Group Inc. (anciennement Meso Numismatics, Inc.) a annoncé une importante refonte de sa marque, changeant son nom et son symbole boursier en RMTG. Ce changement, qui prendra effet le 21 octobre 2024, marque la transition complète de l'entreprise de la numismatique à la biotechnologie et à la médecine régénérative.
Le PDG David Christensen a exprimé son enthousiasme à l'égard de ce jalon, soulignant la conviction de l'entreprise que la médecine régénérative représente l'avenir de la guérison en santé. L'entreprise prévoit de tirer parti des dernières connaissances, de technologies inclusives et de formations pratiques à travers sa International Society for Stem Cell Applications (ISSCA).
Le marché mondial de la médecine régénérative, évalué à environ 35 milliards de dollars en 2022, devrait croître à plus de 190 milliards de dollars d'ici 2032. RMTG vise à se positionner dans ce domaine en pleine expansion en développant des thérapies avancées pour la réparation, la régénération et la revitalisation des tissus et des organes.
Regenerative Medical Technology Group Inc. (ehemals Meso Numismatics, Inc.) hat eine bedeutende Umfirmierung bekannt gegeben und seinen Namen und sein Aktienkürzel auf RMTG geändert. Diese Änderung, die am 21. Oktober 2024 in Kraft tritt, markiert den vollständigen Übergang des Unternehmens von der Numismatik zur Biotechnologie und regenerativen Medizin.
CEO David Christensen äußerte seine Begeisterung über diesen Meilenstein und betonte den Glauben des Unternehmens an die regenerative Medizin als die Zukunft der Gesundheitsheilung. Das Unternehmen plant, das neueste Wissen, inklusive Technologien und praxisnahe Schulungen über seine International Society for Stem Cell Applications (ISSCA) zu nutzen.
Der globale Markt für regenerative Medizin, der 2022 auf etwa 35 Milliarden Dollar geschätzt wurde, wird voraussichtlich bis 2032 auf über 190 Milliarden Dollar wachsen. RMTG zielt darauf ab, sich in diesem schnell wachsenden Bereich zu positionieren, indem es fortschrittliche Therapien zur Reparatur, Regeneration und Revitalisierung von Geweben und Organen entwickelt.
- None.
- None.
We are thrilled to announce our corporate name change from Meso Numismatics, Inc. to Regenerative Medical Technology Group
LAS VEGAS, NV / ACCESSWIRE / October 21, 2024 / Regenerative Medical Technology Group Inc. ("Regen Med Tech Group" or the "Company"), formerly "Meso Numismatics, Inc. ($MSSV), a renowned leader in regenerative medicine, is pleased to announce that it has changed its name to Regenerative Medical Technology Group ($RMTG). This corporate action will take effect at the open of business on 10/21/2024.
RMTG Square Logo
Breakthroughs in Regenerative Medicine Mark the Company's Future Focus
MIAMI, FL - We are thrilled to announce our corporate name change from Meso Numismatics, Inc. to Regenerative Medical Technology Group. This rebranding marks a significant and eagerly anticipated shift in the company's direction, symbolizing its full transition from the numismatics industry to a leader in biotechnology and regenerative medicine. Our new stock symbol RMTG represents the new name and direction.
David Christensen, CEO of Regenerative Medical Technology Group, expressed his excitement about this milestone: "We are grateful to announce this much anticipated change, and final step in transitioning from the Numismatics industry into Biotechnology. We believe that Regenerative Medicine is the future of health healing, and are excited to deploy the latest knowledge, most inclusive technology, and hands-on training through our own ISSCA (International Society for Stem Cell Applications)."
In 2022, the global Regenerative Medicine Market was valued at approximately 35 billion U.S. dollars and is expected to increase to over 190 billion U.S. dollars by 2032. (According to Statista) https://www.statista.com/statistics/800676/global-market-volume-for-regenerative-medicine/#:~:text=In%
The company's new focus includes the development of advanced therapies designed to repair, regenerate, and revitalize tissues and organs. With a commitment to innovation, patient outcomes, and comprehensive education, Regenerative Medical Technology Group is positioning itself in the rapidly growing field of regenerative medicine.
About Global Stem Cells Group
Global Stem Cells Group Remains an innovator in the Industry. Their commitment to excellence sets it apart from the competition. By continually thinking in ways that others do not, GSCG remains a pioneering force in regenerative medicine. Its approach involves not only developing cutting-edge products but also fostering a collaborative environment with researchers, healthcare providers, and industry experts to ensure the highest standards of quality and efficacy. GSCG's comprehensive education and training programs further underscore their dedication to advancing the field, ensuring that medical professionals worldwide are well-equipped to utilize the latest regenerative therapies. GSCG is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare.
For more information on Global Stem Cells Group please visit: www.stemcellsgroup.com
About Regenerative Medical Technology Group
Regen Med Tech Group is a regenerative medicine company offering diverse products and services through its wholly owned subsidiary Global Stem Cells Group. Global Stem Cells Group is an innovative provider of regenerative medicine solutions, dedicated to advancing healthcare through innovative patient therapies. With a global presence and a multidisciplinary team of experts, the organization strives to harness the potential of stem cells and regenerative medicine to improve patient outcomes across various medical fields. Through its extensive network of clinics, research facilities, and training centers, Global Stem Cells Group is committed to pushing the boundaries of regenerative medicine and making a positive impact on global healthcare. The Company also distributes stem cells and other regenerative based cell lines, and equipment internationally and likewise specializes in education and training physicians in the area of regenerative medicine.
Please see this and other Company filings at www.sec.gov.
Forward Looking Statements
Some information in this document constitutes forward-looking statements or statements which may be deemed or construed to be forward-looking statements, such as the closing of the share exchange agreement. The words "plan", "forecast", "anticipates", "estimate", "project", "intend", "expect", "should", "believe", and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve, and are subject to known and unknown risks, uncertainties and other factors which could cause the Company's actual results, performance (financial or operating) or achievements to differ from the future results, performance (financial or operating) or achievements expressed or implied by such forward-looking statements. The risks, uncertainties and other factors are more fully discussed in the Company's filings with the U.S. Securities and Exchange Commission. All forward-looking statements attributable to the Company herein, including those related to the opening of the Regenerative Medicine Clinic and Laboratory and its ability to expand into the UAE markets for regenerative care, are expressly qualified in their entirety by the above-mentioned cautionary statement. The Company disclaims any obligation to update forward-looking statements contained in this estimate, except as may be required by law.
Contact Information
Investor Relations
investor.relations@regenmedtechgroup.com
(800) 956-3935
Related Video
https://www.youtube.com/watch?v=Xc3LYP-tl2A
SOURCE: Investor Relations
View the original press release on accesswire.com
FAQ
What is the new name and ticker symbol for Meso Numismatics?
When will the RMTG stock symbol change take effect?
What is the main focus of Regenerative Medical Technology Group (RMTG)?
How large is the global Regenerative Medicine Market expected to be by 2032?
What organization does RMTG use for stem cell applications training?
